TITLE

Prophylaxis of Deep Vein Thrombosis and Pulmonary Embolism: Current Recommendations

AUTHOR(S)
Hull, Russell D.; Pineo, Graham F.
PUB. DATE
April 1998
SOURCE
Clinical & Applied Thrombosis/Hemostasis;Apr1998, Vol. 4 Issue 2, p96
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Pulmonary embolism remains a major cause of death in high-risk medical and surgical patients. This is unfortunate as effective measures for prevention of venous thromboembolism in such patients are now available. Based on Level 1 evidence from clincial trials and systematic reviews, recommendations can be made for the prevention of venous thromboembolism in most situations. If such information is not available, recommendations based on extrapolation from similar risk situations or from consensus opinions must be used. Additional clinical trials are required to fill in such gaps in our knowledge and permit adequate protection against fatal pulmonary embolism in most if not all medical and surgical patients.
ACCESSION #
16707450

 

Related Articles

  • Venous thromboembolism. Blann, Andrew D.; Li, Gregory Y.H. // BMJ: British Medical Journal (International Edition);1/28/2006, Vol. 332 Issue 7535, p215 

    The article presents a clinical review of the risks, onset, pathology, prevention and treatment of venous thromboembolism. The condition, comprising both deep vein thrombosis and pulmonary embolism, are commonly seen in hospitals. Risk factors include age, cancer, thrombophilia, and recent...

  • Fondaparinux is as effective and safe as unfractionated heparin for pulmonary embolism.  // BMJ: British Medical Journal (International Edition);3/6/2004, Vol. 328 Issue 7439, p532 

    Raises the question of whether or not fondaparinux is as safe and effective as unfractionated heparin for treating pulmonary embolism. How alternatives to unfractionated heparin are widely used for treating deep vein thrombosis; Level of evidence.

  • Fondaparinux is as effective and safe as unfractionated heparin for pulmonary embolism.  // BMJ: British Medical Journal (International Edition);3/6/2004, Vol. 328 Issue 7439, p532 

    Raises the question of whether or not fondaparinux is as safe and effective as unfractionated heparin for treating pulmonary embolism. How alternatives to unfractionated heparin are widely used for treating deep vein thrombosis; Level of evidence.

  • Formulary management of low molecular weight heparins. Wade, W.E.; Martin, B.C.; Kotzan, J.A.; Spruill, W.J.; Chisoholm, M.A.; Perri, M. // PharmacoEconomics;2000, Vol. 17 Issue 1, p1 

    Low molecular weight heparins (LMWHs) are increasingly being utilised as anticoagulants in healthcare settings. These agents offer several advantages over standard unfractionated heparin. Indications for LMWHs include deep vein thrombosis and pulmonary embolism prophylaxis, deep vein thrombosis...

  • Thromboprophylaxis does not protect severely injured patients against pulmonary embolism. Velmahos, George C.; Toutouzas, Konstantinos G.; Brown, Carlos; Vassiliu, Pantelis; Gkiokas, George; Rhee, Peter // American Surgeon;Oct2004, Vol. 70 Issue 10, p893 

    The existing evidence on the effectiveness of thromboprophylaxis after trauma is conflicting. Although prophylaxis with heparin and/or sequential compression devices is practiced widely, many studies failed to document a clear benefit. A recent meta-analysis suggests that prophylaxis does not...

  • Clinical: Managing suspected DVT at home. Sherifi, Jim // GP: General Practitioner;10/14/2005, p56 

    The article focuses on the treatment of DVT outside hospital. The incidence of clinically evident venous thrombosis in Great Britain is 1-2 per 1,000 adults each year. It can result in significant morbidity and mortality due to pulmonary embolism. The use of low molecular weight heparin and...

  • Low molecular weight heparin for deep vein thrombosis in glioma patients. Schmidt, Friederike; Faul, Christoph; Dichgans, Johannes; Weller, Michael // Journal of Neurology;Oct2002, Vol. 249 Issue 10, p1409 

    The treatment and secondary prophylaxis of deep vein thrombosis (DVT) and pulmonary embolism, a common complication in patients with malignant glioma, has remained controversial. We treated 11 patients with malignant glioma and DVT prospectively with low molecular weight heparin (LMWH) at 175...

  • The Role of Vena Caval Filters in the Management of Venous Thromboembolism. Jacobs, David G.; Sing, Ronald F. // American Surgeon;Aug2003, Vol. 69 Issue 8, p635 

    Deep venous thrombosis (DVT) and pulmonary embolism (PE) are important, and not infrequent, causes of morbidity and mortality in critically ill patients. Anticoagulation remains the treatment of choice for DVT and PE, but contraindications to, and complications from, anticoagulant therapy...

  • THE MANAGEMENT AND MISMANAGEMENT OF ACUTE VENOUS THROMBOSIS (THROMBOPHLEBITIS) OF THE EXTREMITIES. Morris, Leslie E.; Balk, Philip // Angiology;Jun1965, Vol. 16 Issue 6, p339 

    In the treatment of acute venous thrombosis of the extremities, bed rest and antibiotics are not only useless but dangerous. Fibrinolysin is of doubtful value, is very expensive, requires complicated laboratory techniques and carries the hazard of homologous serum hepatitis. Ligation of the...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics